Morning Review on Top Gainers -- Research on Banco Santander Brasil, Novavax, Cadence Design Systems, and Amicus Therapeutics

LONDON, April 30, 2014 /PRNewswire/ --

The US markets saw a positive sentiment on Tuesday, April 29, 2014, with the NASDAQ Composite closing at 4,103.54, up 0.72%, the Dow Jones Industrial Average ending the session 0.53% higher at 16,535.37, and the S&P 500 edging 0.48% higher to finish the trading session at 1,878.33. During the session gains in the Financials, Information Technology and Materials sectors positively impacted the broader market, while some retraction came in from Utilities and Consumer Staples sectors. A number of stocks saw large movements, including Banco Santander Brasil S.A. (NYSE: BSBR), Novavax Inc. (NASDAQ: NVAX), Cadence Design Systems Inc. (NASDAQ: CDNS) and Amicus Therapeutics Inc. (NASDAQ: FOLD). Free technical research on BSBR, NVAX, CDNS and FOLD can be downloaded upon signing up at:

http://www.investor-edge.com/1913-register

Banco Santander Brasil S.A.'s stock finished Tuesday's session 13.84% higher at $6.58. A total of 65.47 million shares were traded, which was much above its three months average volume of 5.81 million shares. The stock moved between $6.49 and $6.93 during the session. Over the last one month, and previous three months, Banco Santander Brasil S.A.'s shares have rallied 22.53% and 35.67%, respectively. Additionally, from the start of this year, the company's stock has gained upside of 21.61%. The S&P 500 Financials Sector Index mapped a gain of 0.95% during the trading session, and the same charted up 4.30% in the previous three months. The company's shares are trading above its 50-day and 200-day moving averages of $5.27 and $5.46, respectively. Banco Santander Brasil S.A.'s stock has a Relative Strength Index (RSI) of 61.46. On April 29, 2014, Banco Santander Brasil S.A. announced its Q1 FY2014 financial results. For Q1 FY 2014, the company reported net profit attributable to Banco Santander Brasil S.A. of EUR 1.303 billion. Sign up today to read free research on BSBR at:

http://www.investor-edge.com/1913-BSBR-30Apr2014.pdf

On Tuesday, shares of Novavax Inc. fluctuated between $4.05 and $4.63 before ending the session 13.96% higher at $4.49. Novavax Inc.'s stock reported a trading volume of 9.49 million shares, above to its three months average volume of 4.57 million shares. Novavax Inc.'s shares have advanced 8.72% in the previous three trading sessions and 5.90% in the last one month. However, from the beginning of 2014, the company's stock has declined 12.30%. The S&P 500 Health Care Sector Index registered a gain of 0.62% during the trading session, and the same has charted up 4.72% in the last three months. The stock is trading above its 200-day moving average of $4.03. Moreover, shares of the company have an RSI of 39.42. Sign up today to read free research on NVAX at:

http://www.investor-edge.com/1913-NVAX-30Apr2014.pdf

Cadence Design Systems Inc.'s stock advanced 4.39%, closing the day at $15.46. The stock recorded a trading volume of 9.01 million shares, much above to its three months average volume of 3.33 million shares. The stock oscillated between $14.90 and $15.60 during the trading session. Over the previous three trading sessions and over the last three months, Cadence Design Systems Inc.'s shares have gained 2.72% and 9.80%, respectively. Additionally, the stock has advanced 10.27% since the start of this year. The S&P 500 Information Technology Sector Index reported a gain of 0.74% during the trading session and charted up 6.26% in the last three months. The stock is trading above its 50-day and 200-day moving averages. The stock's 50-day moving average of $15.21 is above its 200-day moving average of $14.22. Additionally, the stock traded at a PE ratio of 29.82 and has an RSI of 45.22. Sign up today to read free research on CDNS at:

http://www.investor-edge.com/1913-CDNS-30Apr2014.pdf

On Tuesday, shares of Amicus Therapeutics Inc. recorded a trading volume of 5.41 million shares, higher than its three months average volume of 0.32 million shares. The stock ended the day at $2.22, which was 20.65% above its previous day's closing, and registered an intraday range of $2.18 and $2.50. Amicus Therapeutics Inc.'s shares have surged 18.72% in the previous three trading sessions, and 8.82% in the last one month. However, the stock has lost 5.53%, since start of this year. The S&P 500 Health Care Sector Index mapped a gain of 0.62% during the trading session, and the index has charted up 4.72% in the previous three months. The company's stock is trading below its 50-day and 200-day moving averages of $2.23 and $2.36, respectively. Furthermore, shares of the company have an RSI of 33.84. Sign up today to read free research on FOLD at:

http://www.investor-edge.com/1913-FOLD-30Apr2014.pdf


===============
EDITOR'S NOTES:
===============

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.investor-edge.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.investor-edge.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.investor-edge.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Investor-Edge, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Investor-Edge in this article or report according to the procedures outlined by Investor-Edge. Investor-Edge is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Investor-Edge makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Investor-Edge is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Investor-Edge whatsoever for any direct, indirect or consequential loss arising from the use of this document. Investor-Edge expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Investor-Edge does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Investor-Edge.com

SOURCE Investor-Edge

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED